Welcome to our dedicated page for Davita news (Ticker: DVA), a resource for investors and traders seeking the latest updates and insights on Davita stock.
DaVita Inc. provides comprehensive kidney care through a global dialysis and care-delivery network. Company news commonly covers quarterly operating results, revenue per treatment, patient care costs, reimbursement trends, share repurchases and investor conference participation.
Updates also address DaVita's value-based kidney care programs, coordinated care arrangements, and services that support patients across stages and settings of kidney disease, including home support, outpatient dialysis centers, hospitals, skilled nursing facilities and transplantation-related care.
Alebund Pharmaceuticals (stock code: 09637.HK) reported unaudited 2026 interim results for the six months ended June 30, 2026. Revenue rose to RMB104.2 million from RMB12.1 million (+761.2%), driven mainly by RMB79.3 million AP306 licensing revenue from R1 Therapeutics and RMB24.8 million Mircera® sales (+105.0% year-on-year). Net loss narrowed 22.5% to RMB162.6 million, and adjusted net loss decreased 12.6% to RMB130.1 million.
R&D expenses increased 28.4% to RMB141.4 million. Cash, cash equivalents, time deposits, and wealth management products reached RMB1,392.8 million, up 162.2%. Key pipeline milestones included completion of AP301 global Phase III enrollment and China NDA acceptance, initiation of the AP306 global Phase IIb trial, positive AP303 Phase I data, and promising AP308 preclinical results. The company listed its H shares in Hong Kong in June 2026, raising net proceeds of about HK$1,355.8 million, including HK$184.7 million from an over-allotment option.
DaVita (NYSE:DVA) announced a new value-based care agreement with Humana to deliver comprehensive, coordinated care for more than 10,000 Humana Medicare Advantage members with chronic kidney disease (CKD) stages 3B–5. Launched July 1, the partnership expands the companies’ long-standing collaboration in end stage kidney disease to earlier stages, where interventions are intended to have greater impact.
Care is delivered through DaVita Integrated Kidney Care, which provides whole-person, coordinated management of cardiovascular, kidney and metabolic health, aiming to reduce care fragmentation and avoidable hospitalizations. The model leverages DaVita’s network of 3,000 value-based nephrologist partners and offers interdisciplinary support, education on home dialysis and kidney transplantation, and help with barriers such as nutrition, transportation and mental health as patients approach potential kidney failure.
DaVita (NYSE: DVA) reported second quarter 2026 revenues of $3.554 billion, operating income of $579 million (16.3% margin) and diluted EPS of $4.02. Net income attributable to DaVita was $265 million. Operating cash flow reached $490 million, with free cash flow of $256 million.
The company added a $500 million Term Loan B-2 tranche, using part to repay its revolving credit balance and retaining the remainder for general corporate purposes. DaVita repurchased 2.2 million shares for $348 million in Q2 and an additional 0.2 million shares for $37 million after quarter-end.
Total U.S. dialysis treatments were 7.23 million (92,649 per day), with revenue per treatment of $415.87 and patient care costs of $277.40. As of June 30, 2026, DaVita served about 298,500 patients at 3,266 centers and had 64,900 patients in risk-based integrated kidney care arrangements, representing approximately $5.8 billion in annualized medical spend. 2026 guidance includes adjusted operating income of $2.15–$2.25 billion, adjusted diluted EPS of $14.10–$15.20 and free cash flow of $1.0–$1.25 billion.
DaVita (NYSE: DVA) will host its quarterly investor conference call to discuss second quarter 2026 results on Tuesday, August 4, 2026, at 5:00 p.m. Eastern Time. Results will be released after market close the same day, with live webcast and replay available via the DaVita investor relations website.
DaVita (NYSE:DVA) unveiled its 2030 Community Care commitments after achieving most prior five-year ESG goals. New targets focus on patient outcomes, teammate opportunity, and community and environmental resilience.
Plans include expanded kidney education, more transplants, sustained high engagement, greater volunteerism, and continued 100% renewable energy use.
DaVita (NYSE: DVA) announced that CFO Joel Ackerman and Group VP of Investor Relations Nic Eliason will speak in a fireside chat at the BofA Securities 2026 Health Care Conference on May 12, 2026 at 5:20 PM ET. A live webcast is available via the BofA page with free registration.
As of March 31, 2026, DaVita served approximately 296,300 patients at 3,262 outpatient dialysis centers worldwide, including 2,666 US centers and 596 centers across 14 other countries.
DaVita (NYSE: DVA) reported Q1 2026 results for the quarter ended March 31, 2026. Consolidated revenue was $3.416 billion, operating income $482 million, diluted EPS from continuing operations $2.87, operating cash flow $321 million and free cash flow $140 million. The company repurchased 3.0 million shares for $403 million in Q1 and repurchased an additional 2.0 million shares for $302 million through May 5, 2026.
As of March 31, 2026, DaVita served ~296,300 patients at 3,262 centers and had ~62,600 patients in risk-based integrated kidney care representing ~$5.4 billion annualized medical spend.
Honeywell (NASDAQ: HON) announced the anticipated 11‑member Board of Directors for the planned standalone Honeywell Aerospace, led by Independent Chair Craig Arnold and including CEO Jim Currier. The spin‑off is expected to be completed on June 29, 2026, with an Investor Day scheduled for June 3, 2026.
The board combines aerospace, defense, finance, and capital‑markets experience intended to support electrification, autonomy, and safety initiatives as the company launches as a public pure‑play aerospace and defense firm.
DaVita (NYSE: DVA) will host its first quarter 2026 earnings conference call on Tuesday, May 5, 2026 at 5:00 p.m. Eastern Time. The company will release results after market close the same day and will webcast the call on its investor relations site.
Investors can join via webcast or by dialing the provided domestic and international numbers; a website replay will be available after the live event.
DaVita (NYSE:DVA) highlighted progress in value-based kidney care on March 18, 2026, citing improved quality metrics, shared savings and scale in coordinated care.
Key points: a 9% Total Quality Score improvement, >$200 million in cumulative shared savings, and management of $5+ billion in medical costs under management, tied to better treatment starts and reduced catheter use.